![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1665268
½Å°æº¸Ã¶ ½ÃÀå : ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2025-2034³â)Neuroprosthetics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 |
¼¼°èÀÇ ½Å°æº¸Ã¶ ½ÃÀåÀº 2024³â¿¡´Â 155¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2025³âºÎÅÍ 2034³â±îÁö CAGR 12.7%·Î È®´ëµÉ °ÍÀ¸·Î ¿¹ÃøµÇ¾î ÇöÀúÇÑ ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ¼ºÀåÀº ½Å°æ Áúȯ À¯º´·üÀÇ »ó½Â°ú ÃÖ÷´Ü ¿þ¾î·¯ºí ½Å°æº¸Ã¶ ±â¼úÀÇ Ã¤¿ë Áõ°¡¿¡ ÀÇÇÑ Á¡ÀÌ Å®´Ï´Ù. °³¹ß µµ»ó Áö¿ªÀÇ ÀÇ·á Á¢±Ù¼º Çâ»ó°ú ȯÀÚ¿Í ÀÇ·á Á¦°ø¾÷ü °£ÀÇ ½Å°æº¸Ã¶ÀÇ º¯ÇõÀû ÀÌÁ¡¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ´Ù´Â °ÍÀÌ ¼ö¿ä¸¦ ´õ¿í ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÷´Ü ½Å°æÇÐÀû Ä¡·á¿¡ ´ëÇÑ Á¤ºÎÀÇ Áö¿ø°ú ÀÚ±Ý Áö¿ø ÀÌ´Ï¼ÅÆ¼ºê´Â ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ ÀåºñÀÇ ÀáÀç·ÂÀ» È®´ëÇϰí ÀÖ½À´Ï´Ù.
À¯Çüº°·Î ¿îµ¿±â Àΰø Àåºñ°¡ ½ÃÀåÀ» µ¶Á¡Çϰí CAGRÀº 12.5%, 2034³â¿¡´Â 230¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºê·¹ÀÎ ¸Ó½Å ÀÎÅÍÆäÀ̽º(BMI)¿Í ½Å°æ Á¦¾î ½Ã½ºÅÛÀÇ È¹±âÀûÀÎ Áøº¸´Â ÀÇÁö Àåºñ¿¡ Çõ¸íÀ» °¡Á® ¿ÔÀ¸¸ç, ÀÚ¿¬½º·´°í È¿À²ÀûÀÎ ÀÛµ¿À» À§ÇÑ ³ú¿Í ÀåÄ¡ÀÇ ¿øÈ°ÇÑ Ä¿¹Â´ÏÄÉÀ̼ÇÀ» °¡´ÉÇÏ°Ô Çß½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀº ÀçȰ Ä¡·á¿¡¼ Á¡Á¡ ´õ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ°Ô µÇ°í, ÀÒ¾î¹ö¸° ¿îµ¿ ±â´ÉÀÇ È¸º¹À» µ½°í, ¿îµ¿±â º¸Á¶ÀåÄ¡ ½ÃÀå¿¡¼ÀÇ Á¸Àç°¨À» È®°íÇÏ°Ô Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
½ÃÀÛ ¿¬µµ | 2024³â |
¿¹Ãø ¿¬µµ | 2025-2034³â |
½ÃÀÛ ±Ý¾× | 155¾ï ´Þ·¯ |
¿¹Ãø ±Ý¾× | 510¾ï ´Þ·¯ |
CAGR | 12.7% |
±â¼úº°·Î ºÐ·ùÇϸé ô¼öÀڱؿä¹ý(SCS)ÀÌ 2024³â Á¡À¯À² 36.7%·Î ½ÃÀåÀ» ¼±µµÇß½À´Ï´Ù. SCS ÀåÄ¡´Â ½Å°æ º´Áõ ÅëÁõ, µî ¼ö¼ú ½ÇÆÐ ÁõÈıº, º¹ÇÕ¼º ±¹¼Ò ÅëÁõ ÁõÈıºÀÇ Ä¡·á¿¡ ÇÊ¿äÇÕ´Ï´Ù. ¸¸¼º ÅëÁõ °ü¸®¿¡¼ SCSÀÇ È¿´ÉÀÌ ÀÔÁõµÊ¿¡ µû¶ó SCS´Â ȯÀÚ ¹× ÀÇ·á Á¦°ø¾÷ü¿¡°Ô ¼±È£µÇ´Â ¼Ö·ç¼ÇÀ¸·Î È®¸³µÇ¾î ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ÀÌÁ¡À» º¸ÀåÇÕ´Ï´Ù.
¹Ì±¹¿¡¼ ½Å°æº¸Ã¶ ½ÃÀåÀº 2024³â¿¡ 66¾ï ´Þ·¯¸¦ Â÷ÁöÇßÀ¸¸ç, 2034³â±îÁö 12%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ¼ºÀåÀ» µÞ¹ÞħÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â ³ª¶óÀÇ °í·ÉÈ, ÆÄŲ½¼º´À̳ª °£Áú µî ½Å°æÁúȯÀÇ ÀÌȯÀ² Áõ°¡¸¦ µé ¼ö ÀÖ½À´Ï´Ù. °ß°íÇÑ »óȯ ½ÃÃ¥°ú ¼±µµÀûÀÎ Á¦Á¶¾÷üÀÇ Á¸Àç°¡ ½ÃÀå È®´ë¸¦ ´õ¿í µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. ÀÇ·á±â¼úÀÇ ²÷ÀÓ¾ø´Â Áøº¸¿Í ½Å°æÇÐÀû Äɾ ´ëÇÑ ÁÖ·ÂÀÇ °È·Î ¹Ì±¹Àº ¼¼°èÀÇ ½Å°æº¸Ã¶ »ê¾÷¿¡ ÀÖ¾î¼ÀÇ Çõ½Å°ú ¼ºÀåÀÇ Áß¿äÇÑ °ÅÁ¡À¸·Î¼ È®°íÇÑ ÁöÀ§¸¦ ±¸ÃàÇϰí ÀÖ½À´Ï´Ù.
The Global Neuroprosthetics Market was valued at USD 15.5 billion in 2024 and is poised for remarkable growth, projected to expand at a CAGR of 12.7% from 2025 to 2034. This growth is largely attributed to the rising prevalence of neurological disorders and the increasing adoption of cutting-edge wearable neuroprosthetic technologies. Enhanced healthcare accessibility in developing regions and growing awareness of neuroprosthetics' transformative benefits among patients and healthcare providers are further driving demand. Additionally, government support and funding initiatives for advanced neurological treatments are broadening the potential of these innovative devices.
By type, motor prosthetics are positioned to dominate the market, with a projected CAGR of 12.5%, reaching USD 23 billion by 2034. Groundbreaking advancements in brain-machine interfaces (BMIs) and neural control systems have revolutionized motor prosthetics, enabling seamless brain-to-device communication for natural and efficient movements. These technologies are playing an increasingly vital role in rehabilitation therapies, helping restore lost motor functions and solidifying the strong market presence of motor prosthetics.
Market Scope | |
---|---|
Start Year | 2024 |
Forecast Year | 2025-2034 |
Start Value | $15.5 Billion |
Forecast Value | $51 Billion |
CAGR | 12.7% |
When categorized by technique, spinal cord stimulation (SCS) leads the market with a 36.7% share in 2024. SCS devices have become a cornerstone in the treatment of neuropathic pain, failed back surgery syndrome, and complex regional pain syndrome. Their proven efficacy in managing chronic pain has established them as the preferred solution for patients and healthcare providers alike, ensuring their sustained market dominance.
In the United States, the neuroprosthetics market accounted for USD 6.6 billion in 2024 and is expected to grow at a CAGR of 12% through 2034. Key factors fueling this growth include the country's aging population and the increasing incidence of neurological conditions such as Parkinson's disease and epilepsy. Robust reimbursement policies and the presence of leading manufacturers further bolster market expansion. Continuous advancements in medical technology and an intensified focus on neurological care firmly position the U.S. as a critical hub for innovation and growth in the global neuroprosthetics industry.